Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

Changes in the immune system induced by tyrosine kinase inhibitors (TKI) have been shown to positively correlate with therapy responses in chronic myeloid leukemia (CML). However, only a few longitudinal studies exist and no randomized comparisons between two TKIs have been reported. Therefore, we p...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncoimmunology
Glavni autori: Kreutzman, Anna, Yadav, Bhagwan, Brummendorf, Tim H., Gjertsen, Bjorn Tore, Hee Lee, Moon, Janssen, Jeroen, Kasanen, Tiina, Koskenvesa, Perttu, Lotfi, Kourosh, Markevärn, Berit, Olsson-Strömberg, Ulla, Stentoft, Jesper, Stenke, Leif, Söderlund, Stina, Udby, Lene, Richter, Johan, Hjorth-Hansen, Henrik, Mustjoki, Satu
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2019
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6685516/
https://ncbi.nlm.nih.gov/pubmed/31428530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2019.1638210
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items